Unfit individuals also have the alternative of venetoclax plus obinutuzumab (VO) as frontline therapy. This is based on a period III trial that compared VO with ClbO in aged/unfit people.113 VO was top-quality when it comes to reaction fee and progression-free survival, and experienced a equivalent safety profile. In this demo VO was administered f